Results 31 to 40 of about 2,579 (176)

Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence

Neuropsychiatric Disease and Treatment, 2023
Tuan Vu,1 Heinz Wiendl,2 Masahisa Katsuno,3 Stephen W Reddel,4 James F Howard Jr5 1Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, USA; 2Department of Neurology with Institute of Translational Neurology ...
Vu T, Wiendl H, Katsuno M, Reddel SW, Howard JF Jr   +4 more
doaj   +3 more sources

Ravulizumab in adults and children with atypical hemolytic uremic syndrome: a plain language summary of three studies

Journal of Comparative Effectiveness Research
This summary gives an overview of three published articles that report the results of research studies of ravulizumab, an approved treatment for people with atypical hemolytic uremic syndrome (often shortened to aHUS).
Michal Nowicki, Nikoleta Printza
doaj   +2 more sources

Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria [PDF]

Haematologica, 2020
Eculizumab is first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH); however, approximately 11%-27% of patients may experience breakthrough hemolysis (BTH) on approved doses of eculizumab.
Robert A. Brodsky, Régis Peffault de Latour, Scott T. Rottinghaus, Alexander Röth, Antonio M. Risitano, Ilene C. Weitz, Peter Hillmen, Jaroslaw P. Maciejewski, Jeff Szer, Jong Wook Lee, Austin G. Kulasekararaj, Lori Volles, Andrew I. Damokosh, Stephan Ortiz, Lori Shafner, Peng Liu, Anita Hill, Hubert Schrezenmeier   +17 more
doaj   +2 more sources

Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studies

Journal of Comparative Effectiveness Research
What is this summary about? Generalized myasthenia gravis (often shortened to gMG) is a rare health condition that causes muscular weakness. This summary gives an overview of three published articles that report the results of research studies of a ...
Florencia Aguirre, Renata Andrade
doaj   +2 more sources

Ravulizumab and Efgartigimod in Myasthenia Gravis

Neurology Neuroimmunology & Neuroinflammation
Finanziert durch den Open-Access-Publikationsfonds der Universität Münster.
Frauke Stascheit, Carla Daiane Ferreira de Sousa, Annette Aigner, Malina Behrens, Christian W. Keller, Luisa Klotz, Sophie Lehnerer, Maike Stein, Meret Herdick, Paolo Doksani, Lea M. Gerischer, Sarah Hoffmann, Konstantinos Lazaridis, John Tzartos, Heinz Wiendl, Andreas Meisel, Jan D. Lünemann   +16 more
openaire   +5 more sources

Analysis of adverse drug reactions associated with ravulizumab: a retrospective pharmacovigilance study utilizing the FAERS database [PDF]

Frontiers in Immunology
BackgroundRavulizumab is a long-acting C5 complement inhibitor that provides sustained suppression of the complement pathway. It is currently approved by the US Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis ...
Yue Zhou, Yutong Wu, Yingchao Su, Zhaoyou Meng   +3 more
doaj   +2 more sources

A case report on the effective and safe use of ravulizumab in atypical hemolytic uremic syndrome during pregnancy [PDF]

BMC Nephrology
Background Atypical hemolytic uremic Syndrome (aHUS), a form of thrombotic microangiopathy (TMA), had a poor prognosis until the development of complement C5-inhibiting monoclonal antibodies, eculizumab and ravulizumab.
Abdulaziz Alkhaldi, Mamoun Elawad, Sultan Al Dalbhi, Bandar Alquraini, Alanoud Alshannan   +4 more
doaj   +2 more sources

Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder [PDF]

Neurology and Therapy
Introduction Anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) is a complement-mediated autoimmune disease in which unpredictable and relapsing attacks on the central nervous system cause irreversible and ...
Stacey L. Clardy, Sean J. Pittock, Orhan Aktas, Jin Nakahara, Noriko Isobe, Diego Centonze, Sami Fam, Adrian Kielhorn, Jeffrey C. Yu, Jeroen Jansen, Ina Zhang   +10 more
doaj   +2 more sources

Real-World Case Series of Ravulizumab Use in Patients with Myasthenia Gravis in Romania

Brain Sciences
Background and Objectives: Ravulizumab, a long-acting C5 complement inhibitor, was approved in the US and Europe in 2022 as an add-on therapy for the standard treatment of AChR-positive generalized MG (gMG).
Crisanda Vîlciu, Oana Antonia Mihalache, Bogdan Marius Istrate, Mihaela Aftinia Marian, Mirela Ramona Drăghici, Diana Mihaela Petrescu, Adriana Octaviana Dulămea, Daniela Cristina Anghel   +7 more
doaj   +2 more sources

Disease Activity After Switching From Eculizumab to Ravulizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria: Real World Data From Denmark and Finland [PDF]

eJHaem
Introduction Ravulizumab replaced eculizumab as the preferred complement inhibitor for Paroxysmal Nocturnal Haemoglobinuria (PNH) in Denmark and Finland after 2020. Data on real‐world disease activity after switching are limited.
Anders Rønneholt‐Frederiksen, Dennis Lund Hansen, Vuokko Nummi, Jesper Stentoft, Ulrik M. Overgaard, Rie Sander Bech, Anna‐Elina Lehtinen, Andreas Glenthøj, Henrik Frederiksen   +8 more
doaj   +2 more sources